<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138733</url>
  </required_header>
  <id_info>
    <org_study_id>BPR-CS-009</org_study_id>
    <nct_id>NCT03138733</nct_id>
  </id_info>
  <brief_title>Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of ceftobiprole medocaril
      versus a comparator in the treatment of patients with complicated Staphylococcus aureus
      bacteremia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall success at the post-treatment evaluation (PTE) visit</measure>
    <time_frame>Day 70±5</time_frame>
    <description>Comparison of overall success rates in the modified intent-to-treat (mITT) population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at the PTE visit</measure>
    <time_frame>Day 70±5</time_frame>
    <description>Comparison of all-cause mortality rates in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological eradication at the PTE visit</measure>
    <time_frame>Day 70±5</time_frame>
    <description>Comparison of microbiological eradication rates in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall success at the PTE visit</measure>
    <time_frame>Day 70±5</time_frame>
    <description>Comparison of overall success rates in the clinically evaluable (CE) population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of new metastatic foci or other complications of SAB after Day 7</measure>
    <time_frame>Day 70±5</time_frame>
    <description>Comparison of complication rates in the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Staphylococcus aureus bloodstream clearance</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Time-to-event comparison in the mITT and CE populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, type, severity, and relationship to study medication of adverse events; and changes in laboratory tests</measure>
    <time_frame>Up to Day 70±5</time_frame>
    <description>Treatment-emergent adverse events; safety laboratory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ceftobiprole maximum plasma concentration</measure>
    <time_frame>Day 3 and Day 12</time_frame>
    <description>Ceftobiprole plasma concentrations at various time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ceftobiprole area under the concentration-time curve</measure>
    <time_frame>Day 3 and Day 12</time_frame>
    <description>Ceftobiprole plasma concentrations at various time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Staphylococcus Aureus Bacteremia</condition>
  <arm_group>
    <arm_group_label>Ceftobiprole medocaril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftobiprole medocaril 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daptomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daptomycin 6 mg/kg, with or without Aztreonam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftobiprole medocaril</intervention_name>
    <description>Ceftobiprole medocaril 500 mg as 2 h infusion</description>
    <arm_group_label>Ceftobiprole medocaril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>Daptomycin 6 mg/kg as 0.5 h infusion, with or without Aztreonam</description>
    <arm_group_label>Daptomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 years of age

          -  Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture
             obtained within the 72 h prior to randomization

          -  At least two of the following signs or symptoms of bacteremia:

               1. fever ≥ 38°C/100.4°F

               2. white blood cell count &gt; 10,000 or &lt; 4,000 cells/µL, or &gt; 10% immature
                  neutrophils (bands)

               3. tachycardia (heart rate &gt; 90 bpm)

               4. hypotension (systolic blood pressure &lt; 90 mmHg)

          -  At least one of the following:

               1. SAB in patients undergoing chronic intermittent hemodialysis or peritoneal
                  dialysis

               2. Persistent SAB

               3. Definite native-valve right-sided infective endocarditis by Modified Duke's
                  Criteria

               4. Other forms of complicated SAB

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Treatment with potentially effective (anti-staphylococcal) systemic antibacterial
             treatment for more than 48 h within the 7 days prior to randomization; Exception:
             Documented failure of bloodstream clearance

          -  Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that
             are known to be non-susceptible to either ceftobiprole or aztreonam

          -  Left-sided infective endocarditis

          -  Prosthetic cardiac valves or valve support rings, cardiac pacemakers, automatic
             implantable cardioverter-defibrillator, or left-ventricular assist devices

          -  Community- or hospital-acquired pneumonia

          -  Opportunistic infections within 30 days prior to randomization, where the underlying
             cause of these infections is still active

          -  Requirement for continuous renal-replacement therapy

          -  Women who are pregnant or nursing

          -  Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamal Hamed, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamal Hamed, MD, MPH</last_name>
    <phone>+41 61 567 15 88</phone>
    <email>kamal.hamed@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Engelhardt, MD</last_name>
    <phone>+41 61 567 15 46</phone>
    <email>marc.engelhardt@basilea.com</email>
  </overall_contact_backup>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Ceftobiprole</mesh_term>
    <mesh_term>Ceftobiprole medocaril</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

